B. Riley Financial Forecasts Strong Price Appreciation for Theravance Biopharma (NASDAQ:TBPH) Stock

Theravance Biopharma (NASDAQ:TBPH) had its price objective hoisted by investment analysts at B. Riley Financial from $14.00 to $17.00 in a report released on Tuesday,Benzinga reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. B. Riley Financial’s price objective suggests a potential upside of 2.41% from the stock’s current price.

Several other analysts also recently issued reports on TBPH. Oppenheimer downgraded Theravance Biopharma from an “outperform” rating to a “market perform” rating in a report on Thursday, March 5th. BTIG Research restated a “buy” rating and set a $21.00 price objective on shares of Theravance Biopharma in a report on Friday, March 20th. HC Wainwright boosted their price objective on Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Wall Street Zen downgraded Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a report on Monday. Finally, Zacks Research upgraded Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a report on Thursday, March 19th. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $21.83.

Theravance Biopharma Stock Up 0.2%

NASDAQ:TBPH opened at $16.60 on Tuesday. The business’s 50-day moving average price is $16.86 and its 200 day moving average price is $17.02. The firm has a market cap of $854.73 million, a P/E ratio of 8.18 and a beta of 0.17. Theravance Biopharma has a 52-week low of $8.09 and a 52-week high of $21.03.

Insider Transactions at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $13.96, for a total transaction of $433,695.32. Following the sale, the senior vice president owned 232,699 shares in the company, valued at approximately $3,248,478.04. The trade was a 11.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On Theravance Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in Theravance Biopharma by 2.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company’s stock valued at $32,289,000 after acquiring an additional 54,152 shares in the last quarter. State Street Corp grew its stake in Theravance Biopharma by 4.4% during the 4th quarter. State Street Corp now owns 1,101,892 shares of the biopharmaceutical company’s stock valued at $20,616,000 after acquiring an additional 45,987 shares in the last quarter. Geode Capital Management LLC grew its stake in Theravance Biopharma by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 938,724 shares of the biopharmaceutical company’s stock valued at $17,567,000 after acquiring an additional 40,734 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Theravance Biopharma by 12.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 858,957 shares of the biopharmaceutical company’s stock valued at $16,072,000 after acquiring an additional 92,253 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new position in Theravance Biopharma during the 3rd quarter valued at about $10,611,000. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.